AU Patent

AU2022405067A1 — Heterocyclic compounds as kit kinase inhibitors

Assigned to Deciphera Pharmaceuticals LLC · Expires 2024-06-20 · 2y expired

What this patent protects

Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.

USPTO Abstract

Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022405067A1
Jurisdiction
AU
Classification
—
Expires
2024-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.